Kamada (NASDAQ:KMDA) Earns Buy Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Kamada (NASDAQ:KMDA) in a report published on Thursday morning. The firm issued a buy rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a buy rating and set a $11.00 price objective on shares of Kamada in a report on Thursday, May 9th.

Kamada Trading Up 1.6 %

Shares of KMDA opened at $5.30 on Thursday. The company has a market cap of $304.64 million, a PE ratio of 23.04 and a beta of 1.05. The stock has a 50-day moving average price of $5.43 and a 200-day moving average price of $5.60. Kamada has a 12-month low of $4.08 and a 12-month high of $6.53.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.04. The firm had revenue of $36.43 million during the quarter, compared to the consensus estimate of $37.71 million. Kamada had a return on equity of 5.50% and a net margin of 8.33%. As a group, analysts predict that Kamada will post 0.23 earnings per share for the current year.

Hedge Funds Weigh In On Kamada

Large investors have recently modified their holdings of the company. Y.D. More Investments Ltd raised its holdings in shares of Kamada by 107.1% during the 4th quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 15,000 shares in the last quarter. Calton & Associates Inc. bought a new stake in Kamada in the fourth quarter valued at approximately $111,000. EWA LLC bought a new stake in Kamada in the fourth quarter valued at approximately $68,000. Vanguard Group Inc. lifted its position in Kamada by 8.2% in the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock valued at $7,433,000 after purchasing an additional 100,800 shares during the last quarter. Finally, Aristides Capital LLC lifted its position in Kamada by 41.6% in the fourth quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock valued at $347,000 after purchasing an additional 16,635 shares during the last quarter. 20.38% of the stock is owned by hedge funds and other institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.